The results suggest that relatively narrow-spectrum, well-tolerated TKIs may be effective in the treatment of imatinib and sunitinib-resistant GIST, and that mutated KIT may thus frequently remain a key target in advanced GIST that has become resistant to one or more TKIs. This evidence concerns the gene KIT and gastrointestinal stromal tumor.